Abstract
• Identify, assure, and measure major sources of variability affecting the MRI-directed biopsy pathway for prostate cancer diagnosis. • Develop strategies to control and minimize variations that impair pathway effectiveness including the performance of main players and team working. • Assure end-to-end quality of the diagnostic chain with robust multidisciplinary team working.
Original language | English |
---|---|
Pages (from-to) | 4386-4389 |
Number of pages | 4 |
Journal | European Radiology |
Volume | 31 |
Issue number | 6 |
DOIs | |
Publication status | Published - Jun 2021 |